Home Compliance Will FDA and DOJ Reassert Their Enforcement Muscle With Life Sciences in... ComplianceExpert OpinionFCANews Will FDA and DOJ Reassert Their Enforcement Muscle With Life Sciences in 2022? January 25, 2022 29 Share FacebookLinkedinTwitter grandbrothers | Shutterstock You must be a Paid or Free Trial Member to Access this Content. Paid members, please login to view your news subscription(s). RELATED ARTICLESMORE FROM AUTHOR Claims The Agency Stopped Work Due to COVID. Why Couldn’t this Contractor Recover Costs Under the Contract’s Suspension of Work Clause? Compliance Scope and Impact of the FTC’s Non-Compete Rule for Employers Compliance CISA Unveils Final Self-Attestation Form for Software Producers Bidding on Federal Contracts